Consistently, DNMT3A, TET2, and ASXL1 mutations, which are most commonly associated with age-related clonal hematopoiesis, during complete remission phase did not increase risk of relapse in AML41, whereas other mutations such as U2AF1 and RUNX1 (absent in CH) could associate with relapse and lower rates of relapse-free survival6,42. The gene discussed is RUNX1; the disease is cyclic hematopoiesis.